Metformin, Macrophage Dysfunction and Atherosclerosis.

Area of Science:

• Immunology
• Pharmacology
• Metabolic Diseases

Background:

• Metformin is a widely used hypoglycemic drug with potential pleiotropic effects.
• Macrophages play a crucial role in the pathogenesis of atherosclerosis and other inflammatory diseases.
• Dysfunctional macrophages contribute to various pathological conditions, suggesting therapeutic targets.

Purpose of the Study:

• To summarize the current understanding of metformin's effects on macrophage function.
• To explore the molecular mechanisms underlying metformin's immunomodulatory actions.
• To discuss future research directions and therapeutic strategies involving metformin and macrophages.

Main Methods:

• Literature review and synthesis of existing studies on metformin and macrophage biology.
• Analysis of molecular pathways regulated by metformin in macrophages, including AMPK, NF-κB, and Sirt1.
• Identification of emerging research areas such as single-cell RNA sequencing and epigenetic modifications.

Main Results:

• Metformin modulates macrophage differentiation, inflammation, oxidative stress, polarization, foam cell formation, and apoptosis.
• Key regulatory pathways include AMPK-dependent and independent mechanisms, NF-κB, ABCG5/8, Sirt1, FOXO1/FABP4, and HMGB1.
• Metformin's influence on macrophages is central to its pleiotropic pharmacological profile.

Conclusions:

• Improving macrophage dysfunction is a key mechanism for metformin's broad therapeutic effects.
• Future research should focus on advanced techniques like single-cell RNA sequencing and epigenetic analysis.
• Combination therapies, such as metformin with SGLT2 inhibitors or statins, hold promise for treating atherosclerosis, obesity, cancer, dementia, and aging.